U.S. Medical Equipment Stock News

Match Group (MTCH) is back in focus after first quarter results that topped analyst revenue expectations, came with solid EBITDA figures, and included updated full year guidance that management framed as a strong start. See our latest analysis for Match Group. The stock trades at US$36.13, with a 90 day share price return of 14.34% and a 1 year total shareholder return of 23.54%. However, the 5 year total shareholder return is down 72.86%, so recent momentum contrasts with a much weaker...

Why Enphase Energy (ENPH) Is Back on Investors’ Radar Enphase Energy (ENPH) has quietly moved higher recently, with the stock up over the past week, month, and past 3 months. This has prompted investors to reassess what is driving sentiment around the solar technology company. See our latest analysis for Enphase Energy. That recent 30 day share price return of 119.17% and year to date share price return of 102.55% contrast with a 3 year total shareholder return that is down 62.41%. This...

Biogen (BIIB) is in focus after two headline events: a first quarter 2026 earnings beat with steady revenue guidance but lower earnings expectations, and the discontinuation of a Phase 2b Parkinson’s candidate. See our latest analysis for Biogen. At a share price of US$196.0, Biogen’s 1-year total shareholder return of 51.01% contrasts with a 3-year total shareholder return that declined 34.71% and a 5-year total shareholder return that declined 31.50%. This suggests recent momentum has...

Earlier this week, JPMorgan upgraded Allient (NASDAQ: ALNT), a precision motion systems provider in defense, automation, and humanoid robotics, expressing greater confidence in its business outlook. The bank’s view that Allient is well positioned across defense, factory automation, and emerging humanoid robot applications highlights how its motion technologies span both established and developing industrial markets. Next, we’ll examine how JPMorgan’s focus on Allient’s role in humanoid...

Investors may be wondering whether Williams-Sonoma stock still offers value after a strong run, or if most of the opportunity is already priced in. The stock closed at US$203.57, with returns of 5.8% over 7 days, 12.4% over 30 days, 8.4% year to date, 27.7% over 1 year and a very large 3 year return, alongside a 168.8% return over 5 years. This performance can change how the market views its risk and reward profile. Recent coverage has focused on how Williams-Sonoma fits into broader retail...

Viridian Therapeutics has now fully repaid approximately US$55.10 million under its Hercules term loan and entered a long-term commercial manufacturing services agreement under which WuXi Biologics will supply veligrotug for potential commercial use. Together, the debt payoff and manufacturing pact highlight Viridian’s shift toward a less leveraged balance sheet and greater operational readiness for potential product launch. We’ll now examine how Viridian’s full debt repayment shapes its...

This article walks through the key numbers that shape the view on whether Dutch Bros at around US$58 is starting to look expensive, still reasonable, or somewhere in between. The stock has risen about 11.3% over the past week and 4.8% over the past month, even though it is still down 6.7% year to date and 19.7% over the last year, so the recent move may have your attention. Recent company news has focused on Dutch Bros' ongoing store expansion, brand presence and market positioning, which...

Elastic FY 2026 earnings snapshot Elastic (ESTC) has wrapped up FY 2026 with Q4 revenue of US$450.7 million and basic EPS of US$4.18, while trailing twelve month EPS sits at US$3.49 on revenue of US$1.7 billion and net income of US$367.8 million. Over recent quarters, the company has seen revenue range from US$388.4 million in Q4 FY 2025 to US$450.7 million in Q4 FY 2026, with basic EPS moving from a loss of US$0.16 to a profit of US$4.18 as interim periods included both losses and modest...

Axsome Therapeutics (AXSM) stock has been drawing attention after a period of strong share price moves, including gains over the past month and past 3 months. This has prompted investors to reassess its current valuation and risk profile. See our latest analysis for Axsome Therapeutics. Beyond the recent rally, Axsome Therapeutics has seen its 30 day share price return of 27.47% build on a 90 day share price return of 43.07%. The 1 year total shareholder return of 122.97% and 5 year total...

The European Commission has opened an in depth investigation into JD.com's proposed acquisition of German electronics retailer Ceconomy under the EU's Foreign Subsidies Regulation. The probe focuses on alleged Chinese state subsidies and is the first full scale review of a Chinese outbound deal under this framework. The outcome could shape conditions for JD.com's European expansion and set a reference point for future Chinese cross border acquisitions. For investors following JD.com...

Investors may be wondering if Lumentum Holdings at around US$854.96 is still offering value after its big run, or if the easy money has already been made. The stock is up 121.4% year to date, with a very large 1 year return and a multi year gain of more than 7x, even though it has fallen 9.7% over the past week and is down 0.4% over the past month. Recent attention on Lumentum Holdings has been driven by its share price performance and the broader interest in evaluating high growth tech...

Sunrun stock at a glance after recent price move Sunrun (RUN) has drawn fresh attention after recent trading left the stock at US$16.72, with gains over the past week, month, and past 3 months prompting investors to reassess the residential solar player. See our latest analysis for Sunrun. Sunrun’s recent US$16.72 share price comes after short term share price returns of 31.34% over 30 days and 26.19% over 90 days. The 1 year total shareholder return of 123.23% contrasts with weaker 3 and 5...

EverCommerce (EVCM) is back in focus after fiscal Q1 results came in slightly ahead of guidance, with revenue supported by subscription and transaction fees, prompting analysts to reaffirm confidence despite ongoing questions about the company’s longer term business trajectory. See our latest analysis for EverCommerce. The stock has reacted positively to the Q1 update in the very short term, with a 1-day share price return of 1.44% and a 7-day share price return of 5.24%. However, the 30-day...

Recent performance snapshot TJX Companies (TJX) has drawn investor attention after a mixed near term share performance, with the stock roughly flat year to date but down over the past month and past 3 months. Despite this softer recent stretch, TJX remains a large off price retailer with a market value of about US$171.3b and annual revenue of US$61.6b. Its business spans apparel, home fashions and related categories. See our latest analysis for TJX Companies. Recent share price momentum has...

At FormFactor’s May 15, 2026 annual meeting, shareholders approved an amendment to the company’s Amended and Restated Certificate of Incorporation following a period of strong Q1 fiscal 2026 results and rising demand for its DRAM-focused testing solutions. The company’s increasingly important role in providing cryogenic infrastructure for quantum computing, alongside growing AI-related test demand, underscores how its specialized tools are becoming embedded in next‑generation semiconductor...

Why PennyMac Financial Services (PFSI) is on investor radars PennyMac Financial Services (PFSI) has drawn attention after a period of weaker share performance, with the stock down over the past month and past three months. This has prompted some investors to take a closer look at its underlying business trends. See our latest analysis for PennyMac Financial Services. At the latest share price of $83.87, PennyMac Financial Services has seen its short term momentum fade, with the 30 day share...

Wondering if Corning at US$181.16 is priced for perfection or still offers value? This article walks through the key numbers so you can judge for yourself. The stock has been volatile recently, with a decline of 6.6% over the last 7 days, a 19.3% gain over 30 days, and year-to-date and 1-year returns of 99.8% and 269.3% that many long-term holders will be watching closely. Recent coverage around Corning has focused on its role in technology supply chains and how investor expectations are...

Zenas BioPharma (ZBIO), a clinical-stage immunology specialist, continues to attract attention after a year in which the stock’s total return is reported at 93.28%, contrasting with a year-to-date decline of 46.67%. See our latest analysis for Zenas BioPharma. At the latest share price of $18.40, Zenas BioPharma’s recent 7 day and 90 day share price returns show declines, yet its 1 year total shareholder return of 93.28% still points to earlier gains, indicating that momentum has faded...

Recent performance snapshot ASML Holding (NasdaqGS:ASML) has drawn fresh attention after recent trading, with the stock last closing at $1,612.76. Investors are weighing this price against its long run of strong multi year total returns. See our latest analysis for ASML Holding. Short term sentiment has cooled slightly, with a 7 day share price return of 1.23% and a 90 day share price return of 11.18%. The 1 year total shareholder return of 120.35% highlights how strong longer term momentum...

Recent share performance snapshot Revolve Group (RVLV) has drawn attention after a period of weaker share performance, with the stock down about 24% over the past month and about 22% over the past 3 months. Over the past year, the stock is lower by about 5%, while the year-to-date return is down roughly 34%. This pullback comes against a backdrop of annual revenue of about US$1.27b and net income of roughly US$64.24m. See our latest analysis for Revolve Group. At a share price of US$19.60,...

Target (NYSE:TGT) is phasing out cereals containing synthetic food dyes across all stores. The company is aligning cereal assortments with evolving FDA guidance and consumer health preferences. The shift affects relationships with major cereal suppliers and will require product reformulations or assortment changes. For investors, this move sits at the intersection of food retail, regulation, and consumer health. Target already competes in a crowded grocery space where shoppers are paying...

Earlier this week, Adtran and euNetworks announced they had launched Quantum Shield, a quantum-safe private connectivity service built on Adtran’s FSP 3000 encrypted optical transport platform to secure high-capacity data center traffic across euNetworks’ pan-European network. The collaboration highlights Adtran’s role in enabling quantum-resistant, regulation-ready encryption and real-time fiber monitoring for European enterprises facing tighter cybersecurity and post-quantum compliance...

In recent days, Astera Labs’ co-founders Jitendra Mohan, Sanjay Gajendra and Casey Morrison won the 2026 EY World Entrepreneur Of The Year award, while the company continued to highlight broad demand for its AI data center connectivity solutions, including its expanding Scorpio, Leo and Taurus product lines. This combination of global entrepreneurial recognition and deep involvement in next-generation open AI infrastructure platforms underscores how central Astera Labs has become to...

Investors may be wondering whether Berkshire Hathaway stock at around US$474 per share still offers value, or if most of the opportunity is already priced in. The stock is down 2.4% over the last week, 0.2% over the last month, 4.5% year to date and 5.8% over the last year. The 3 year and 5 year returns stand at 44.0% and 62.2% respectively. Recent headlines have focused on Berkshire Hathaway's role as a diversified financial giant and on ongoing interest in its portfolio and capital...